# Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis

> **NCT00506519** · PHASE2 · TERMINATED · sponsor: **LEO Pharma** · enrollment: 25 (actual)

## Conditions studied

- Disseminated Intravascular Coagulation

## Interventions

- **DRUG:** Antithrombin alfa (INN name)
- **DRUG:** Control (Standard treatment)

## Key facts

- **NCT ID:** NCT00506519
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00506519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00506519, "Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00506519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*